neurotrophic signaling raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-08 and is reviewed periodically as new material appears.
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Identity and purity are established with standard peptide methods. Reversed-phase HPLC with ultraviolet detection near 214 nm resolves the parent peak from deletion and truncation byproducts, and reports typically quote a main-peak percentage. Mass spectrometry by electrospray or MALDI-TOF confirms the expected molecular mass, while amino acid analysis or peptide mapping can verify composition when the sequence itself is in question. A certificate of analysis that pairs a chromatogram with a mass spectrum is more informative than a purity figure alone. Counter-ion content and residual solvents are separate specifications and are frequently omitted.
Semax is normally supplied as a lyophilized powder, and that form is the most stable. Suppliers commonly recommend storage at -20 °C in a desiccated container protected from light, with short-term handling at room temperature limited to weighing and transfer. Powder that has absorbed moisture degrades faster, so vials should be warmed to ambient temperature before opening to prevent condensation on the contents. Hygroscopic behavior is typical of short hydrophilic peptides, and humidity control matters more than temperature alone for long-term retention.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide (ACTH fragment analog) | Not a steroid; does not belong to the melanocortin agonist drugs by marketing category |
| Molecular formula | C37H51N9O10S (commonly cited) | Reported values vary slightly with salt and counter-ion content |
| Appearance | White to off-white lyophilized powder | A single batch may appear as a loose cake or fluffy solid |
| Solubility | Freely soluble in water and aqueous buffer | Stock solutions are usually prepared in sterile water or saline |
| Typical storage | −20 °C or below, desiccated and protected from light | Seal opened vials promptly to limit moisture uptake |
Development took place during the 1980s at institutes of the Russian Academy of Sciences, where peptide fragments of ACTH were screened for cognitive and neuroprotective effects. The compound received regulatory approval in Russia as a nasal preparation, marketed for conditions such as ischemic stroke, transient ischemic attacks, and optic nerve disorders. Registration in other countries has not followed. Most published clinical reports originate from a small number of Russian research groups, and independent replication outside that setting remains limited. The regulatory status therefore differs sharply between Russia and the rest of the world.
Laboratory work points toward modulation of neurotrophic signaling, particularly expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal tissue. Studies also describe effects on monoamine turnover, inflammatory mediators, and oxidative markers. These observations come mainly from animal models and cultured cells, so the causal chain in humans is not firmly established. Whether the reported molecular changes translate into measurable clinical benefit is an open question. Reviews generally present the mechanism as plausible rather than demonstrated.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
A study conducted by researchers at the University of Alabama examined the adhesive properties of fibrin tissue adhesives. The tests found that fibrin adhesives even at its intended medical concentration (29 mg/mL at the wound site) had shear strength of only 17.6 kiloPascals. Furthermore, another study performed at the University of California determined that the modulus (the stress/strain) of fibrin adhesives was on average 53.56 kPA. To seal together tissues the human body uses collagen and elastin to obtain superior shear strength. Type I collagen which includes collagen strands bundled into strong fibrils has a unique tri-helical structure which increases the proteins structural integrity. In fact, a study performed by the Department of Medicine in University College London experimentally determined that pure type I collagen has a modulus of 5 GPa to 11.5 GPa. Therefore, pure type I collagen has nearly one million times greater structural integrity than fibrin. Collagen is therefore much harder to deform than fibrin, and collagen fibers create much stronger bonds between tissues than strands of fibrin polymer.
=== Molecular target === Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of 1 mole docetaxel per mole tubulin in microtubules. This binding stabilizes microtubules and prevents depolymerisation from calcium ions, decreased temperature and dilution, preferentially at the plus end of the microtubule. Docetaxel has been found to accumulate to higher concentration in ovarian adenocarcinoma cells than kidney carcinoma cells, which may contribute to the more effective treatment of ovarian cancer by docetaxel. It has also been found to lead to the phosphorylation of oncoprotein bcl-2, which is apoptosis-blocking in its oncoprotein form.
In lean and obese mice, these benefits of BCAA-restriction are mediated by isoleucine and valine, and not by restriction of leucine. Restriction of dietary BCAAs extends lifespan in flies, while restriction of BCAAs in mice extends male lifespan and decreased frailty, but does not extend female lifespan. In mice, dietary supplementation with BCAAs alone decreases lifespan and promotes obesity. However, consumption of a BCAA-enriched essential amino acid supplement extends the lifespan of mice.
Most charts or tables indicate the type of friction factor, or at least provide the formula for the friction factor with laminar flow. If the formula for laminar flow is f = 16/Re, it is the Fanning factor f, and if the formula for laminar flow is fD = 64/Re, it is the Darcy–Weisbach factor fD. Which friction factor is plotted in a Moody diagram may be determined by inspection if the publisher did not include the formula described above:
Although not without conflict, European Canadians' early interactions with First Nations and Inuit populations were relatively peaceful. First Nations and Métis peoples played a critical part in the development of European colonies in Canada, particularly for their role in assisting European coureurs des bois and voyageurs in their explorations of the continent during the North American fur trade. These early European interactions with First Nations would change from friendship and peace treaties to the dispossession of Indigenous lands through treaties. Settler colonialism reached a peak in the late 19th and early 20th centuries. The Canadian government funded Indian residential schools, administered by Christian churches, that are considered to be part of a genocide against Indigenous people due to the institutions' use of forced assimilation. In 2021, possible gravesites of Indigenous children were found near former Canadian residential schools, highlighting the cultural genocide against Indigenous peoples. A period of redress began with the formation of a reconciliation commission by the Government of Canada in 2008. This included acknowledgment of a cultural genocide, settlement agreements, and betterment of racial discrimination issues, such as addressing the plight of missing and murdered Indigenous women.
Sources: en.wikipedia.org
In June 1906, President Theodore Roosevelt signed into law the Pure Food and Drug Act of 1906, also known as the "Wiley Act" after its chief advocate. The Act prohibited, under penalty of seizure of goods, the interstate transport of food that had been "adulterated". The act applied similar penalties to the interstate marketing of "adulterated" drugs, in which the "standard of strength, quality, or purity" of the active ingredient was not either stated clearly on the label or listed in the United States Pharmacopeia or the National Formulary. The responsibility for examining food and drugs for such "adulteration" or "misbranding" was given to Wiley's USDA Bureau of Chemistry. Wiley used these new regulatory powers to pursue an aggressive campaign against the manufacturers of foods with chemical additives, but the Chemistry Bureau's authority was soon checked by judicial decisions, which narrowly defined the bureau's powers and set high standards for proof of fraudulent intent. In 1927, the Bureau of Chemistry's regulatory powers were reorganized under a new USDA body, the Food, Drug, and Insecticide Administration. This name was shortened to the Food and Drug Administration (FDA) three years later. By the 1930s, muckraking journalists, consumer protection organizations, and federal regulators began mounting a campaign for stronger regulatory authority by publicizing a list of injurious products that had been ruled permissible under the 1906 law, including radioactive beverages, mascara that could cause blindness, and worthless "cures" for diabetes and tuberculosis.
==== X-ray diffraction ==== A case study by Beale et al. involved preparation of iron phosphates and bismuth molybdate catalysts from an amorphous precursor gel. The study found that there were no intermediate phases in the reaction, and helped to determine kinetic and structural information. The article uses the dated term in-situ, but the experiment uses, in essence, an operando method. Although x-ray diffraction does not count as a spectroscopy method, it is often being used as an operando method in various fields, including catalysis.
The conservation of genetic material with the intention of conserving a breed. The conservation of genetic material is not limited to non-humans. Many services provide genetic storage or the preservation of stem cells at birth. They may be used to study the generation of cell lines or for stem-cell therapy.
== Early life and education == Gibson was born in Montreal and studied psychology at the University of Victoria, where between 1973 and 1974 he drew weekly comics for the student newspaper. After completing his Bachelor of Arts degree in 1974 he moved to Vancouver. He lived in London, England from 1983 to 1989. He received a Master of Science degree in Interactive Art and Technology from Simon Fraser University, Surrey in 2004.
Sources: en.wikipedia.org
==== Post-traumatic growth ==== Posttraumatic growth (PTG) is a possible outcome after a traumatic event, besides posttraumatic stress disorder (PTSD). Following a traumatic event, for instance rape, incest, cancer, attack, or combat, "it is normal to experience debilitating symptoms of depression and anxiety." A person who shows PTG however, will experience these negative outcomes for a time and then show an increase in well-being, higher than it was before the trauma occurred. Martin Seligman, a founder of positive psychology, emphasizes that "arriving at a higher level of psychological functioning than before" is a key point in PTG. If instead an individual experiences a depressive period but recovers from an incident and returns to their normal level of psychological functioning, they are demonstrating resilience. This suggests that in PTG, the trauma acts as a turning point for the person to achieve greater well-being. Seligman recognizes "the fact that trauma often sets the stage for growth" and given the right tools, individuals can make the most of that opportunity." When reflecting on a traumatic growth, Seligman suggests using the following five elements to facilitate PTG: understand the response to trauma, reduce anxiety, utilize constructive disclosure, create a trauma narrative, and articulate life principles and stances that are more robust to challenge.
[C(O)NH]3 ⇌ [C(O)NH]2[C(O)N]− + H+ (pKa = 6.88) [C(O)NH]2[C(O)N]− ⇌ [C(O)NH][C(O)N]22− + H+ (pKa = 11.40) [C(O)NH][C(O)N]22− ⇌ [C(O)N]33− + H+ (pKa = 13.5) Cyanuric acid is noted for its strong interaction with melamine, forming insoluble melamine cyanurate. This interaction locks the cyanuric acid into the tri-keto tautomer. Melamine cyanurate is cited as an example of supramolecular chemistry.
=== Nervous system impairment === The periods before and surrounding birth are typically normal in individuals with LNS. The most common presenting features are abnormally decreased muscle tone (hypotonia) and developmental delay, which are evident by three to six months of age. Affected individuals are late in sitting up, while most never crawl or walk. Irritability is most often noticed along with the first signs of nervous system impairment. Within the first few years of life, extrapyramidal involvement causes abnormal involuntary muscle contractions such as loss of motor control (dystonia), writhing motions (choreoathetosis), and arching of the spine (opisthotonus). Signs of pyramidal system involvement, including spasticity, overactive reflexes (hyperreflexia) and extensor plantar reflexes, also occur. The resemblance to athetoid cerebral palsy is apparent in the neurologic aspects of LNS. As a result, most individuals are initially diagnosed as having cerebral palsy. The motor disability is so extensive that most individuals never walk, and become lifelong wheelchair users.
Sources: en.wikipedia.org
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.
It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.
It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.
Each freeze-thaw cycle can degrade a fraction of the peptide and promote aggregation. Dividing a stock solution into single-use volumes removes repeated cycling as a variable. It also limits the time a thawed solution spends at room temperature.